Cargando…
Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
BACKGROUND: Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients with reduced ejection fraction (HFrEF) is the inhibition of the renin–angiotensin–aldosterone system (RAAS). One of the adverse effects of RAAS blockade is the development of hyp...
Autores principales: | Jiménez-Marrero, Santiago, Enjuanes, Cristina, Yun, Sergi, Comín-Colet, Josep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501904/ https://www.ncbi.nlm.nih.gov/pubmed/32974448 http://dx.doi.org/10.1093/ehjcr/ytaa103 |
Ejemplares similares
-
Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin–Angiotensin–Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective
por: Fischer, Barbara, et al.
Publicado: (2022) -
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021) -
Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
por: Esteban‐Fernández, Alberto, et al.
Publicado: (2022) -
Efficacy and safety of supramaximal titrated inhibition of renin‐angiotensin‐aldosterone system in idiopathic dilated cardiomyopathy
por: He, Zheng, et al.
Publicado: (2015) -
Real-World Epidemiology of Potassium Derangements Among Chronic Cardiovascular, Metabolic and Renal Conditions: A Population-Based Analysis
por: Jiménez-Marrero, Santiago, et al.
Publicado: (2020)